Dr. Udit N Verma, MD

Udit Verma Assistant Professor Professional Experience Residency in Internal Medicine, WVU-Charleston Div, Charleston, WV 1997-1998 Fellowship in Hematology/Oncology, UT Southwestern Medical Center, Dallas, TX 1999-2002 Selected Publications 1.Verma UN et al. IL-2 activation of human bone marrow in long term cultures: an effective strategy for purging and generation of anti-tumor cytotoxic effectors. Bone Marrow Transplant 13: 115, 1994 2.Verma UN et al. IL-2 activation of chemotherapy and growth factor mobilized PBSC for generation of cytotoxic effectors. Bone Marrow Transplant 15: 199, 1995. 3.Verma UN, Mazumder A. IL-12 alone or in synergistic combination with IL-2 for in vitro activation of human bone marrow: differential effects at different time points. Bone Marrow Transplant 16: 365, 1995. 4.Verma UN et al. A syndrome of fibrosing pleuritis, pericarditis and synovitis with infantile contracture of fingers and toes in two sisters: Familial fibrosing serositis. J Rheum 22: 2349, 1995. 5.Wojtowicz-Praga S, Verma UN et al. Anti TGF-a antibody with IL-2 inhibits B16 melanoma growth and metastasis in vivo. J Immunotherapy 19: 3701, 1996. 7.Verma UN et al Effect of the in vivo priming regimen for peripheral blood stem cell mobilization on in vitro generation of cytotoxic effectors by IL-2 activation of PBSC in murine model. Bone Marrow Transplant 19:265 1997 8.Meehan KR; Verma UN; Cahill R et al. IL-2 activated hematopoietic stem cell transplantation for breast cancer: investigation of dose level with clinical correlates. Bone Marrow Transplant 20: 643, 1997 9.Posey JA; Raspet R; Verma U et al. A pilot trial of GM CSF and MDX H210 in patients with erbB 2 positive advanced malignancies. J Immunother 22: 371, 1999 10. Verma UN et al.Paclitaxel vs cyclophosphamide in peripheral blood stem cell mobilization comparative studies in a murine model. Exp Hematol 27: 553, 1999 11.Yamamoto, Y; Kim DW; Kwak YT; Prajapati S; Verma U; Gaynor RB. IKK-?/NEMO fascilitates the recruitment of the IeB proteins into the IeB kinase complex. J Bio Chem 276:36327, 2001 12.Lamberti C; Lin KM; Yamamoto Y; Verma U et al. Regulation of a-catenin function by the IeB kinases. J Bio Chem 276: 42276, 2001 13.Berman K, Verma UN et al.Sulindac enhances TNF-a mediated lung cancer cell apoptosis by inhibition of NF-eB. Clin Cancer Res 8: 354, 2002 14.Verma UN et al. Small interfering RNAs directed against a-catenin inhibit the in vitro and in vivo growth of colon cancer cells. Clin Cancer Res. 9: 1291, 2003 15.Williams NS, Gaynor RB, Scoggin S, Verma UN, et al. Identification and validation of genes involved in the pathogenesis of colorectal cancer utilizing cDNA microarrays and RNA interference. Clin Cancer Res. 9: 931, 2003 16.Yamamoto Y, Verma UN, Prajapati S, and Gaynor RB. A nucleosomal role of IKKalpha in histone H3 phosphorylation is critical for cytokine-induced activation of NF-kB regulated genes. Nature 423: 655, 2003. 17.Prajapati, S., Verma, UN. et al. Protein phosphatase 2Ca association with the IeB kinase complex is involved in regulating NF-eB activity. J Biol Chem 279: 1739, 2004 18.Verma UN, Yamamoto Y, Prajapati and Gaynor RB. Nuclear Role of IKK gamma in NF-kappa B-dependent gene expression. J Biol Chem 279: 3509, 2004 19. Guo J, Verma UN et al.Enhanced Chemosensitivity to Irinotecan by RNA interference mediated down-regulation of the NF-eB p65 subunit. Clin Cancer Res 10, 3333, 2004. 20.Verma UN, Becerra C: The Varied Applications of Small Interference RNA, in Vincent T. DeVita SH, Steven A. Rosenberg (ed): Progress in Oncology 2004. Sudbury, Jones and Barlett, 2005, pp 1-28 21.Kwak YT, Li R, Becerra C, Tripathy D, Frenkel E, Verma UN. IKK alpha regulates sub-cellular distribution and turnover of cyclin D1 by phosphorylation. J Biol Chem. 280: 38888, 2005